(marketscreener.com) Dima, Tristan, & Stephanie LIVING WITH SICKLE CELL DISEASE Corporate Effectiveness Addressing ESG & Long-term Sustainability April...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Corporate-Effectiveness-Report-April-2023-43496530/?utm_medium=RSS&utm_content=20230414

(marketscreener.com) Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilizationFirst immune cell therapy to show a survival benefit in patients with viral acute...https//www.marketscreener.com/quote/stock/MINK-THERAPEUTICS-INC-128249930/news/MiNK-Presents-Clinical-Data-at-SITC-2022-Showcasing-iNKT-Cell-Therapy-Pipeline-42271649/?utm_medium=RSS&utm_content=20221110

San Jose, California–(Newsfile Corp. – December 14, 2022) – Wearing custom cleats designed by Sickle Cell 101, scoring a game-changing touchdown, and winning the AFC Special Teams Player Of The Week, all while advocating for sickle cell—that’s Cleveland Browns’ wide receiver Donovan Peoples-Jones courageously supporting sickle cell for the third year in a row through […]

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

(marketscreener.com) 2021 Annual Report Fueledby Connections A leader in the field of cellular metabolism pioneering therapies for genetically defined diseases Dianaba, Sickle Cell Disease Ryan,...https//www.marketscreener.com/quote/stock/AGIOS-PHARMACEUTICALS-IN-13709228/news/Agios-Pharmaceuticals-View-the-2021-Annual-Report-42514875/?utm_medium=RSS&utm_content=20221209

(marketscreener.com) Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma ...https//www.marketscreener.com/quote/stock/CANDEL-THERAPEUTICS-INC-125090831/news/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develo-42489874/?utm_medium=RSS&utm_content=20221206

ProKidney initiated at equal weight at Morgan Stanley on cell therapy for kidney disease

(marketscreener.com) LONDON, Jan. 09, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc . The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety...https//www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Announces-Collaboration-with-Cabaletta-Bio-for-Use-of-Autolus-Safety-Switch-Sy-42691472/?utm_medium=RSS&utm_content=20230109

A clearer understanding about the markers and drivers of cancer cell proliferation has emerged from research that identifies new opportunities to overcome convergence with complex enzymes, known as kinases. The work paves the way for new approaches to study the molecular drivers of disease states such as cancer.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 ...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691061/?utm_medium=RSS&utm_content=20230109

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 North...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691060/?utm_medium=RSS&utm_content=20230109

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Blood donations are now needed every day to treat people with sickle cell disease.

(marketscreener.com) MALVERN, Pa., Feb. 17, 2023 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton...https//www.marketscreener.com/quote/stock/OCUGEN-INC-19157135/news/Ocugen-to-Present-at-Retinal-Vascular-Disease-Drug-Development-Summit-43019137/?utm_medium=RSS&utm_content=20230217

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient communityhttps//www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics-41933646/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) ― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease ― ― Presented 96-week data from the Phase 2 ReDUX4 trial open label extension study at World Muscle Society conference ― ― Completed equity raise of approximately $80.8 million in net proceeds; Updated cash...https//www.marketscreener.com/quote/stock/FULCRUM-THERAPEUTICS-INC-62037838/news/Fulcrum-Therapeutics-Announces-Recent-Business-Highlights-and-Third-Quarter-2022-Financial-Results-42240611/?utm_medium=RSS&utm_content=20221108

Budget 2023 The health sector has been allocated Rs 89,155 crore in the Union Budget 2023-24, a hike of around 13 per cent over Rs 79,145 crore allocated in 2022-23, with the government also announcing a mission to eliminate sickle cell anaemia by 2047.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) SITC 2022 Abstract 645 Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer ...https//www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-Phase-I-Study-of-Adoptive-T-Cell-Therapy-Following-HER2-Pulsed-Dendritic-Cell-Vaccine-and-42271853/?utm_medium=RSS&utm_content=20221110

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

(marketscreener.com) Company Receives First Major Purchase Order in Saudi ArabiaTORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar...https//www.marketscreener.com/quote/stock/EMMAUS-LIFE-SCIENCES-INC-120797573/news/Emmaus-Life-Sciences-Receives-Endari-Marketing-Authorization-from-the-Qatar-Ministry-of-Public-Heal-42345524/?utm_medium=RSS&utm_content=20221117

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma ...https//www.marketscreener.com/quote/stock/CANDEL-THERAPEUTICS-INC-125090831/news/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develo-42489874/?utm_medium=RSS&utm_content=20221206

Companies investigate how therapies including Crispr might treat a debilitating genetic disease

(marketscreener.com) Novartis said on Mondayits canakinumab drug to help treat non-small cell lung cancerfailed a phase III trial. The drug, used as an adjuvant treatment, did not meet itsprimary endpoint of disease-free survival, the Swiss companysaid. https//www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-says-lung-cancer-drug-canakinumab-failed-phase-III-trial-41313792/?utm_medium=RSS&utm_content=20220815

Demand is at record levels for blood to help people with the disease that mostly affects black people.

Two people with beta thalassaemia and one with sickle cell disease no longer need blood transfusions after their blood stem cells were gene edited and put back in their bodies

A former supervisory correctional officer ordered detainee abuse as well as allowed a white supremacist assault of two Black pretrial inmates.

Development could serve as a catalyst to turn lethal disease into chronic, stable disease.

Development could serve as a catalyst to turn lethal disease into chronic, stable disease.

Treatments involve adding a new gene, or using CRISPR to edit one.

Michael Cohen, who once served as a personal attorney to former President Donald Trump, turned over his cell phones to Manhattan prosecutors this week, CNN reports.This comes as the district attorney’s office investigates the Trump Organization’s role in the “hush money” that was given to former adult film actor Stormy Daniels during Trump’s 2016 presidential campaign. Cohen told CNN host Don Lemon, “Most recently, they asked for my cell phones because they want to be able to extract from it the voice recordings that I had had with Keith Davidson, former attorney to Stormy Daniels...

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

An international team of researchers lays the foundation to examine how extracellular RNA and its carrier proteins found in bodily fluids function in a healthy as well as a diseased setting, potentially providing a means to accurately implement early detection and monitor disease processes.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

BEACON – New York Blood Center will be holding a blood drive at Beacon High School on Wednesday, November 9 from 730 a.m. to 600 p.m. in honor of Paris Moore. The public is encouraged to attend this drive after 230 p.m. if they are able. Paris graduated from Beacon High School in 2018. He was born with […]

2884041 views on Imgur The magic of the Internet

(marketscreener.com) LONDON, Jan. 09, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc . The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety...https//www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Announces-Collaboration-with-Cabaletta-Bio-for-Use-of-Autolus-Safety-Switch-Sy-42691472/?utm_medium=RSS&utm_content=20230109

Research in baboons suggests that misfolded proteins linked to Parkinson’s disease can travel from the brain to gut and vice versa – with both routes causing equal amounts of brain cell death

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Some people who have long lived with the disease say they worry about living as a healthy person, while others worry about the obstacles to getting treatment.

(marketscreener.com) Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Announces-Third-Quarter-2022-Results-and-Business-Updates-42175871/?utm_medium=RSS&utm_content=20221102

Demand for blood donations to treat the disease has risen by 67 per cent over the past five years

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

Understanding when and why a cell dies is fundamental to the study of human development, disease, and aging. For neurodegenerative diseases such as Lou Gehrig’s disease, Alzheimer’s, ...

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.